Drug Screening Market

The drug screening market is projected to reach USD 21.29 billion by 2030 from USD 10.36 billion in 2025, at a high CAGR of 15.5% during the forecast period. Primarily fueled by the growing global use of substances, increasing regulatory scrutiny, and the tangible economic and occupational safety consequences of drug abuse. Recreational and illicit drug use persists globally, with an estimated 6.1% of the global population aged 15-64 using at least one illicit drug per year, as reported by the UNODC and peer-reviewed global prevalence literature. In the European region alone, cannabis, the most widely used illicit drug, was used by 8.4% of the adult population (or 24 million people aged 15-64) in the previous year, reflecting persistent demand for testing. Economic burden is also a very significant global driver, where substance use disorders form the basis of substantial losses in productivity, workplace injuries, absenteeism, and healthcare expenditure, with the US alone reporting close to USD 93 billion in productivity losses in 2023, indicating similar proportional burdens reported by other high- and middle-income nations. In aggregate, these epidemiologic, regulatory, and economic drivers are ensuring that drug screening becomes an integral part of workforce risk management, public health surveillance, and clinical practice, thereby underpinning the growth of the global drug screening market.

The major players operating in the drug screening market are LabCorp (US), Quest Diagnostics Incorporated (US), Abbott (US), OraSure Technologies Inc. (US), Alfa Scientific Designs Inc. (US), Thermo Fisher Scientific Inc. (US), Drägerwerk AG & Co. KGaA (Germany), Lifeloc Technologies, Inc. (US), MPD Inc.  (US), Omega Laboratories, Inc. (US), Premier Biotech, Inc. (US), Psychemedics Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Shimadzu Corporation (Japan), Siemens Healthineers AG (Germany), Bio-Rad Laboratories, Inc. (US), Carehealth America Corp (US), AccusourceHR Inc. (US), Cordant Health Solutions (Australia), Advacare Pharma (US), Millennium Health (US), ACM Global Laboratories (India), Clinical Reference Laboratory Inc. (US), Intoximeters Inc. (US), and Intoxalock (US).

To know about the assumptions considered for the study download the pdf brochure

LabCorp.

The Laboratory Corporation of America Holdings, or LabCorp, is one of the major participants in drug screening and toxicology testing services offered to employers, healthcare organizations, federal and state government institutions, criminal justice systems, and research organizations. The target market offered by LabCorp includes a broad spectrum of businesses and organizations for workplace drug testing programs, labs in healthcare/clinical and forensics, and health organizations at the federal and national level in the US. LabCorp focuses its strategy and plans on working towards increasing its capabilities in drug screening through advancements in analytical capabilities and computerized reporting systems in analytical technology development for faster analysis and adhering to better regulations. Another major area covered in its strategic planning focuses on working towards increasing its toxicology and workplace drug testing product lines through the provision of a variety of test menus (including Opiates, Synthetic/Designer Drugs, and Prescribed Medications) and laboratory information systems for large-scale drug testing programs for its corporate and federal client businesses.  In September 2025, LabCorp announced a collaboration with Roche to adopt FDA-cleared digital pathology slide scanners, advancing digital pathology workflows that improve diagnostic efficiency, accuracy, and AI integration across LabCorp’s laboratory services.

Quest Diagnostics Incorporated

Quest Diagnostics Incorporated is one of the prominent players in the drug screening and toxicology test service sectors, with services provided to employers, the healthcare community, government agencies, law enforcement organizations, and forensic facilities. Quest Diagnostics is one of the largest clinical diagnostic laboratory networks in the US, with services provided for workplace drug testing, clinical toxicology, and regulatory-required screenings performed on various drug categories for various sectors. Quest Diagnostics is primarily focused on improving the speed, scale, and dimension of increased test accuracy and efficiency with the use of sophisticated analytic platforms, automation, and digital reporting systems for various test offerings. Its business plan is based on expanding its integrated drug test panels, such as tests for various types of and uses of narcotics, designer substances, and prescription drug monitoring, and complying with all federal and state regulations.  In November 2024, the company introduced definitive urine drug monitoring panels that detect 113 drugs and volatile compounds, respectively, improving clinical toxicology workflows in emergency and baseline assessments and supporting acute poisoning identification with high specificity and confirmatory precision.

 Abbott

Abbott is one of the strong competitors prevailing in the market for drug screening, offering diverse product lines of fast and convenient point-of-care and laboratory-based drug screening. Abbott serves its customers, such as employers, hospitals, reference labs, and government institutions across the global market, primarily emphasizing the decentralized & on-site drug screening environment. The product development & innovation of Abbott is primarily concentrated on researching & developing new & cutting-edge immunoassay-based screening technology, portable analyzers, and data management tools to provide an easy & quick way for easy outcomes & regulatory requirements. Abbott is primarily helping organizations realize improved security & reduce drug screening program expenses by emphasizing ease of use, turnaround time, and scalable drug screening programs for organizations.

Market Ranking

Organizations, including device manufacturers, diagnostic companies, and lab service providers like Labcorp, Quest Diagnostics Incorporated, Abbott, Thermo Fisher Scientific, Siemens Healthineers, and Roche Diagnostics, are propelling the widespread use of drug screening solutions in organizations, healthcare facilities, and government initiatives. Their comprehensive product portfolios include confirmatory lab-based assays, point-of-care screening systems, high-throughput analyzers, reagents, and lab information systems, thereby aiding a holistic drug testing process. Their large-scale, lab networks, as well as Government regulations awareness, make them leaders in drug screening programs.

At the same time, a number of specialized participants, such as OraSure Technologies, Premier Biotech, Psychemedics Corporation, Omega Laboratories, Alere Toxicology (Abbott), LifeLoc Technologies, MPD Inc., and Drägerwerk AG & Co. KGaA, also have a solid market presence, addressing a specific need in the market that goes beyond the platforms of large integrated providers. They concentrate on oral fluid, hair, breath alcohol, and on-site test offerings, specifically addressing niche needs in employment, law, forensic, and substance abuse markets.

Related Reports:

Drug Screening Market by Offering (On-site Testing, Rapid Testing (Urine, Oral), Analytical (Breathalyzer, Immunoassay, Chromatography)), Sample (Blood, Urine, Hair), Drug (Cannabis, Alcohol), End User (Workplace, Law, Hospitals) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/